Advertisement
U.S. markets closed
  • S&P Futures

    5,080.75
    -0.25 (-0.00%)
     
  • Dow Futures

    38,973.00
    -20.00 (-0.05%)
     
  • Nasdaq Futures

    17,909.50
    -5.75 (-0.03%)
     
  • Russell 2000 Futures

    2,048.40
    +5.00 (+0.24%)
     
  • Crude Oil

    78.38
    -0.16 (-0.20%)
     
  • Gold

    2,044.60
    +1.90 (+0.09%)
     
  • Silver

    22.72
    +0.08 (+0.37%)
     
  • EUR/USD

    1.0839
    -0.0004 (-0.03%)
     
  • 10-Yr Bond

    4.2740
    -0.0410 (-0.95%)
     
  • Vix

    13.84
    +0.41 (+3.05%)
     
  • GBP/USD

    1.2669
    +0.0009 (+0.07%)
     
  • USD/JPY

    149.7780
    -0.8550 (-0.57%)
     
  • Bitcoin USD

    61,584.79
    +4,651.61 (+8.17%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,624.98
    -58.04 (-0.76%)
     
  • Nikkei 225

    38,953.49
    -254.54 (-0.65%)
     

Geron (GERN) Stock Moves -1.78%: What You Should Know

Geron (GERN) closed the most recent trading day at $2.76, moving -1.78% from the previous trading session. This change was narrower than the S&P 500's daily loss of 2%. Meanwhile, the Dow lost 2.06%, and the Nasdaq, a tech-heavy index, lost 2.32%.

Heading into today, shares of the drugmaker had lost 14.07% over the past month, lagging the Medical sector's loss of 0.95% and the S&P 500's gain of 2.88% in that time.

Wall Street will be looking for positivity from Geron as it approaches its next earnings report date. In that report, analysts expect Geron to post earnings of -$0.11 per share. This would mark a year-over-year decline of 10%. Our most recent consensus estimate is calling for quarterly revenue of $0.12 million, down 88.85% from the year-ago period.

It is also important to note the recent changes to analyst estimates for Geron. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Geron is holding a Zacks Rank of #2 (Buy) right now.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 93, which puts it in the top 37% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Geron Corporation (GERN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement